Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: MorphaBond ER Clear all
Completed Phase 4 Interventional Results available

Are Opioids Needed After ACL Reconstruction

NCT04285853
View directory record Official record
Conditions
Anterior Cruciate Ligament Rupture
Interventions
Oxycodone, Placebo oral tablet
Drug
Lead sponsor
Emory University
Other
Eligibility
14 Years to 40 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia • Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 7, 2026, 10:33 AM EDT
Completed Phase 4 Interventional Results available

A Multimodal Analgesia Protocol Adapted for Ambulatory Surgery

NCT04015908
View directory record Official record
Conditions
Opioid Use
Interventions
Celecoxib, Acetaminophen, Pregabalin, Oxycodone, Percocet
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 7, 2024 · Synced Sep 7, 2026, 10:33 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects

NCT00765856
View directory record Official record
Conditions
Chronic Pain
Interventions
Oxymorphone ER
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
13
States / cities
Little Rock, Arkansas • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Sep 7, 2026, 10:33 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

NCT01358526
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone Controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
151
States / cities
Birmingham, Alabama • Haleyville, Alabama • Huntsville, Alabama + 123 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 7, 2026, 10:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Titration of Intravenous Hydromorphone

NCT01892709
View directory record Official record
Conditions
Acute Severe Pain
Interventions
Hydromorphone
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 7, 2026, 10:33 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film

NCT01871285
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine, Placebo film, Oxycodone, Morphine sulfate, Placebo capsule
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Overland Park, Kansas • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 7, 2026, 10:33 AM EDT
Completed Phase 2 Interventional Results available

Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy

NCT03574792
View directory record Official record
Conditions
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
Gabapentin, Methadone, Oxycodone, Quality-of-Life Assessment, Questionnaire Administration, Venlafaxine, Venlafaxine Hydrochloride Extended Release
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 7, 2026, 10:33 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

NCT00580294
View directory record Official record
Conditions
Pain
Interventions
Oxymorphone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 7, 2026, 10:33 AM EDT
Completed Phase 1 Interventional

Low Dose Ketamine for Management of Acute Severe Pain in the Emergency Department

NCT01740492
View directory record Official record
Conditions
Pain
Interventions
Ketamine 0.15mg/kg, Ketamine 0.3mg/kg, Placebo
Drug · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Sep 7, 2026, 10:33 AM EDT
Terminated Phase 4 Interventional Results available

Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills

NCT03588806
View directory record Official record
Conditions
Chronic Pain, Opioid Use, Deglutition
Interventions
Xtampza ER (oxycodone)
Drug
Lead sponsor
Ajay Wasan, MD, Msc
Other
Eligibility
21 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 7, 2026, 10:33 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients

NCT02321319
View directory record Official record
Conditions
Chronic Pain
Interventions
Hydromorphone HCl ER Tablets
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
7 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 7, 2026, 10:33 AM EDT
Terminated Phase 4 Interventional Results available

Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain

NCT02741076
View directory record Official record
Conditions
Opioid-Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
Interventions
Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER), Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
Drug
Lead sponsor
Member Companies of the Opioid PMR Consortium
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
61
States / cities
Foley, Alabama • Mobile, Alabama • Montgomery, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Sep 7, 2026, 10:33 AM EDT
Completed No phase listed Observational

Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB)

NCT04033094
View directory record Official record
Conditions
Baseline Epidemiologic Assessment
Interventions
MorphaBond ER, Comparator Drug
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
Not listed
Enrollment
17,566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Sep 7, 2026, 10:33 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

NCT00505414
View directory record Official record
Conditions
Pain, Neoplasm, Cancer
Interventions
Tapentadol in the Titration Phase, Morphine in the Maintenance Phase, Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase, Tapentadol in the Maintenance Phase, Morphine in the Titration Phase
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
St. Petersburg, Florida • Elkhart, Indiana • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 7, 2026, 10:33 AM EDT
Not listed Not applicable Interventional

A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone

NCT00945919
View directory record Official record
Conditions
Chronic Nociceptive Pain, Neuropathic Pain, Non-cancer Pain
Interventions
Oxymorphone ER
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2009 · Synced Sep 7, 2026, 10:33 AM EDT
Terminated Phase 4 Interventional Results available

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

NCT01100437
View directory record Official record
Conditions
Chronic Pain
Interventions
EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush, EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Sep 7, 2026, 10:33 AM EDT
Completed Phase 2 Interventional

A Study of ARRY-371797 in Patients With Osteoarthritis of the Knee

NCT01366014
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
ARRY-371797, p38 inhibitor; oral, Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral, Placebo; oral
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 85 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Pinellas Park, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 7, 2026, 10:33 AM EDT
Completed Phase 3 Interventional Results available

Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

NCT00415597
View directory record Official record
Conditions
Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 7, 2026, 10:33 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

NCT01400139
View directory record Official record
Conditions
Chronic Nonmalignant and Nonneuropathic Pain
Interventions
Hydrocodone bitartrate q24h film-coated tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 7, 2026, 10:33 AM EDT
Completed Early Phase 1 Interventional

Pilot Trial of Microsphere Oxycodone (Xtampza ER) for Pain Management in Patients Receiving Radiotherapy for Locally Advanced Head and Neck Cancer

NCT03317730
View directory record Official record
Conditions
Locally Advanced Head and Neck Cancer
Interventions
Xtampza ER
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Sep 7, 2026, 10:33 AM EDT
Active, not recruiting Early Phase 1 Interventional

Local Multimodal Injection Versus Regional Anesthesia in Controlling Pain for Treating Rotational Ankle Fractures

NCT05019638
View directory record Official record
Conditions
Ankle Fractures
Interventions
Regional anesthesia group, Local multimodal analgesia group
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 7, 2026, 10:33 AM EDT
Active, not recruiting Early Phase 1 Interventional

Role of Multimodal Analgesia in Decreasing Perioperative Pain in Tibial Plateau Fractures

NCT05037812
View directory record Official record
Conditions
Tibial Plateau Fractures
Interventions
Saline injection, Multimodal injections
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 79 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 7, 2026, 10:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nasal Human Abuse Potential of PTI-821

NCT03475862
View directory record Official record
Conditions
Opioid Abuse Nondependent
Interventions
PTI-821 capsule Manipulated, PTI-821 Non-manipulated, OxyContin, Placebo, Oxycodone
Drug · Other
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 7, 2026, 10:33 AM EDT
Withdrawn Phase 4 Interventional

An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)

NCT01631513
View directory record Official record
Conditions
Pain, Chronic Back Pain, Chronic Low Back Pain, Osteoarthritis Pain In The Hip or Knee
Interventions
Nucynta ER
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Jacksonville, Florida • Prairie Village, Kansas • Mandeville, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 7, 2026, 10:33 AM EDT